Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals.

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for fourth quarter and full year 2025 and provided full year 2026 financial guidance.

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list.

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.